Global Vaginal Candidiasis Market
Global Vaginal Candidiasis Market

Vaginal Candidiasis Comprehensive Study by Treatment (Oral antifungal, Topical imidazole), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), Symptoms (Vaginal itching or soreness, Pain during sexual intercourse, Pain or discomfort when urinating, Abnormal vaginal discharge) Players and Region - Global Market Outlook to 2025

Vaginal Candidiasis Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 215 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Vaginal Candidiasis Market?

Vaginal candidiasis is a fungal infection that causes irritation, discharge and intense itchiness of the vagina and the vulva, the tissues at the vaginal opening. It is commonly called a vaginal yeast infection. This infection affects up to 3 out of 4 women at some point in their lifetimes. It is estimated that 75% of women will have at least one yeast infection in her lifetime. The symptoms of vaginal candidiasis involve itchiness and discomfort.

The market study is being classified and major geographies with country level break-up.

Scynexis (United States), Synmedic Laboratories (India), Merck & Co., Inc. (United States), Astellas (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Abbott (United States), Novartis AG (Switzerland), Pfizer Inc. (United States) and Sanofi (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are ALLERGAN (Ireland) and AstraZeneca (United Kingdom).

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Vaginal Candidiasis market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Vaginal Candidiasis market by Type, Application and Region.

On the basis of geography, the market of Vaginal Candidiasis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Number of Womens Affecting Vaginal Candidiasis
  • Increased Awareness among People about Healthy Lifestyle
  • RIse in the Number of Hospitals and Diagnostic Centres

Market Trend
  • Roust Increase in the Distribution Channels

Restraints
  • Side Effects of the Medications used in Vaginal Candidiasis

Opportunities
  • Increase in Research and Development Expenditure
  • Strong Product Pipeline
  • Growth in the Healthcare Industry

Challenges
  • Stringent Regulatory Conditions in Some Regions


Market Leaders and some development strategies
SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral Ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. The submission is supported by positive results from two Phase 3, randomized, double-blind, placebo-controlled, multi-center studies (VANISH-303 and VANISH-306) in which oral Ibrexafungerp demonstrated statistical superiority over placebo with a favorable tolerability profile.



Key Target Audience
Vaginal Candidiasis Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Oral antifungal
  • Topical imidazole

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By Symptoms
  • Vaginal itching or soreness
  • Pain during sexual intercourse
  • Pain or discomfort when urinating
  • Abnormal vaginal discharge

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Number of Womens Affecting Vaginal Candidiasis
      • 3.2.2. Increased Awareness among People about Healthy Lifestyle
      • 3.2.3. RIse in the Number of Hospitals and Diagnostic Centres
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Conditions in Some Regions
    • 3.4. Market Trends
      • 3.4.1. Roust Increase in the Distribution Channels
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Vaginal Candidiasis, by Treatment, End-users, Distribution Channel, Symptoms and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Vaginal Candidiasis (Value)
      • 5.2.1. Global Vaginal Candidiasis by: Treatment (Value)
        • 5.2.1.1. Oral antifungal
        • 5.2.1.2. Topical imidazole
      • 5.2.2. Global Vaginal Candidiasis by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Vaginal Candidiasis by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online
        • 5.2.3.4. Others
      • 5.2.4. Global Vaginal Candidiasis by: Symptoms (Value)
        • 5.2.4.1. Vaginal itching or soreness
        • 5.2.4.2. Pain during sexual intercourse
        • 5.2.4.3. Pain or discomfort when urinating
        • 5.2.4.4. Abnormal vaginal discharge
      • 5.2.5. Global Vaginal Candidiasis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Vaginal Candidiasis (Volume)
      • 5.3.1. Global Vaginal Candidiasis by: Treatment (Volume)
        • 5.3.1.1. Oral antifungal
        • 5.3.1.2. Topical imidazole
      • 5.3.2. Global Vaginal Candidiasis by: End-users (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Vaginal Candidiasis by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online
        • 5.3.3.4. Others
      • 5.3.4. Global Vaginal Candidiasis by: Symptoms (Volume)
        • 5.3.4.1. Vaginal itching or soreness
        • 5.3.4.2. Pain during sexual intercourse
        • 5.3.4.3. Pain or discomfort when urinating
        • 5.3.4.4. Abnormal vaginal discharge
      • 5.3.5. Global Vaginal Candidiasis Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Vaginal Candidiasis (Price)
  • 6. Vaginal Candidiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Scynexis (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Synmedic Laboratories (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Astellas (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mentis Pharma Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sanofi (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Vaginal Candidiasis Sale, by Treatment, End-users, Distribution Channel, Symptoms and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Vaginal Candidiasis (Value)
      • 7.2.1. Global Vaginal Candidiasis by: Treatment (Value)
        • 7.2.1.1. Oral antifungal
        • 7.2.1.2. Topical imidazole
      • 7.2.2. Global Vaginal Candidiasis by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Vaginal Candidiasis by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online
        • 7.2.3.4. Others
      • 7.2.4. Global Vaginal Candidiasis by: Symptoms (Value)
        • 7.2.4.1. Vaginal itching or soreness
        • 7.2.4.2. Pain during sexual intercourse
        • 7.2.4.3. Pain or discomfort when urinating
        • 7.2.4.4. Abnormal vaginal discharge
      • 7.2.5. Global Vaginal Candidiasis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Vaginal Candidiasis (Volume)
      • 7.3.1. Global Vaginal Candidiasis by: Treatment (Volume)
        • 7.3.1.1. Oral antifungal
        • 7.3.1.2. Topical imidazole
      • 7.3.2. Global Vaginal Candidiasis by: End-users (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Vaginal Candidiasis by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online
        • 7.3.3.4. Others
      • 7.3.4. Global Vaginal Candidiasis by: Symptoms (Volume)
        • 7.3.4.1. Vaginal itching or soreness
        • 7.3.4.2. Pain during sexual intercourse
        • 7.3.4.3. Pain or discomfort when urinating
        • 7.3.4.4. Abnormal vaginal discharge
      • 7.3.5. Global Vaginal Candidiasis Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Vaginal Candidiasis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Vaginal Candidiasis: by Treatment(USD Million)
  • Table 2. Vaginal Candidiasis Oral antifungal , by Region USD Million (2014-2019)
  • Table 3. Vaginal Candidiasis Topical imidazole , by Region USD Million (2014-2019)
  • Table 4. Vaginal Candidiasis: by End-users(USD Million)
  • Table 5. Vaginal Candidiasis Hospitals , by Region USD Million (2014-2019)
  • Table 6. Vaginal Candidiasis Clinics , by Region USD Million (2014-2019)
  • Table 7. Vaginal Candidiasis Others , by Region USD Million (2014-2019)
  • Table 8. Vaginal Candidiasis: by Distribution Channel(USD Million)
  • Table 9. Vaginal Candidiasis Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 10. Vaginal Candidiasis Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 11. Vaginal Candidiasis Online , by Region USD Million (2014-2019)
  • Table 12. Vaginal Candidiasis Others , by Region USD Million (2014-2019)
  • Table 13. Vaginal Candidiasis: by Symptoms(USD Million)
  • Table 14. Vaginal Candidiasis Vaginal itching or soreness , by Region USD Million (2014-2019)
  • Table 15. Vaginal Candidiasis Pain during sexual intercourse , by Region USD Million (2014-2019)
  • Table 16. Vaginal Candidiasis Pain or discomfort when urinating , by Region USD Million (2014-2019)
  • Table 17. Vaginal Candidiasis Abnormal vaginal discharge , by Region USD Million (2014-2019)
  • Table 18. South America Vaginal Candidiasis, by Country USD Million (2014-2019)
  • Table 19. South America Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 20. South America Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 21. South America Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 22. South America Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 23. Brazil Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 24. Brazil Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 25. Brazil Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 26. Brazil Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 27. Argentina Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 28. Argentina Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 29. Argentina Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 30. Argentina Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 31. Rest of South America Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 32. Rest of South America Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 33. Rest of South America Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 34. Rest of South America Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 35. Asia Pacific Vaginal Candidiasis, by Country USD Million (2014-2019)
  • Table 36. Asia Pacific Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 37. Asia Pacific Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 38. Asia Pacific Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 39. Asia Pacific Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 40. China Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 41. China Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 42. China Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 43. China Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 44. Japan Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 45. Japan Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 46. Japan Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 47. Japan Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 48. India Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 49. India Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 50. India Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 51. India Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 52. South Korea Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 53. South Korea Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 54. South Korea Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 55. South Korea Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 56. Taiwan Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 57. Taiwan Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 58. Taiwan Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 59. Taiwan Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 60. Australia Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 61. Australia Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 62. Australia Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 63. Australia Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 65. Rest of Asia-Pacific Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 66. Rest of Asia-Pacific Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 68. Europe Vaginal Candidiasis, by Country USD Million (2014-2019)
  • Table 69. Europe Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 70. Europe Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 71. Europe Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 72. Europe Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 73. Germany Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 74. Germany Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 75. Germany Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 76. Germany Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 77. France Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 78. France Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 79. France Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 80. France Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 81. Italy Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 82. Italy Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 83. Italy Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 84. Italy Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 85. United Kingdom Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 86. United Kingdom Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 87. United Kingdom Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 88. United Kingdom Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 89. Netherlands Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 90. Netherlands Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 91. Netherlands Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 92. Netherlands Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 93. Rest of Europe Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 94. Rest of Europe Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 95. Rest of Europe Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 96. Rest of Europe Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 97. MEA Vaginal Candidiasis, by Country USD Million (2014-2019)
  • Table 98. MEA Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 99. MEA Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 100. MEA Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 101. MEA Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 102. Middle East Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 103. Middle East Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 104. Middle East Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 105. Middle East Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 106. Africa Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 107. Africa Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 108. Africa Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 109. Africa Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 110. North America Vaginal Candidiasis, by Country USD Million (2014-2019)
  • Table 111. North America Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 112. North America Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 113. North America Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 114. North America Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 115. United States Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 116. United States Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 117. United States Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 118. United States Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 119. Canada Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 120. Canada Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 121. Canada Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 122. Canada Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 123. Mexico Vaginal Candidiasis, by Treatment USD Million (2014-2019)
  • Table 124. Mexico Vaginal Candidiasis, by End-users USD Million (2014-2019)
  • Table 125. Mexico Vaginal Candidiasis, by Distribution Channel USD Million (2014-2019)
  • Table 126. Mexico Vaginal Candidiasis, by Symptoms USD Million (2014-2019)
  • Table 127. Vaginal Candidiasis Sales: by Treatment(K Units)
  • Table 128. Vaginal Candidiasis Sales Oral antifungal , by Region K Units (2014-2019)
  • Table 129. Vaginal Candidiasis Sales Topical imidazole , by Region K Units (2014-2019)
  • Table 130. Vaginal Candidiasis Sales: by End-users(K Units)
  • Table 131. Vaginal Candidiasis Sales Hospitals , by Region K Units (2014-2019)
  • Table 132. Vaginal Candidiasis Sales Clinics , by Region K Units (2014-2019)
  • Table 133. Vaginal Candidiasis Sales Others , by Region K Units (2014-2019)
  • Table 134. Vaginal Candidiasis Sales: by Distribution Channel(K Units)
  • Table 135. Vaginal Candidiasis Sales Hospital Pharmacies , by Region K Units (2014-2019)
  • Table 136. Vaginal Candidiasis Sales Retail Pharmacies , by Region K Units (2014-2019)
  • Table 137. Vaginal Candidiasis Sales Online , by Region K Units (2014-2019)
  • Table 138. Vaginal Candidiasis Sales Others , by Region K Units (2014-2019)
  • Table 139. Vaginal Candidiasis Sales: by Symptoms(K Units)
  • Table 140. Vaginal Candidiasis Sales Vaginal itching or soreness , by Region K Units (2014-2019)
  • Table 141. Vaginal Candidiasis Sales Pain during sexual intercourse , by Region K Units (2014-2019)
  • Table 142. Vaginal Candidiasis Sales Pain or discomfort when urinating , by Region K Units (2014-2019)
  • Table 143. Vaginal Candidiasis Sales Abnormal vaginal discharge , by Region K Units (2014-2019)
  • Table 144. South America Vaginal Candidiasis Sales, by Country K Units (2014-2019)
  • Table 145. South America Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 146. South America Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 147. South America Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 148. South America Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 149. Brazil Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 150. Brazil Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 151. Brazil Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 152. Brazil Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 153. Argentina Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 154. Argentina Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 155. Argentina Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 156. Argentina Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 157. Rest of South America Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 158. Rest of South America Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 159. Rest of South America Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 160. Rest of South America Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 161. Asia Pacific Vaginal Candidiasis Sales, by Country K Units (2014-2019)
  • Table 162. Asia Pacific Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 163. Asia Pacific Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 164. Asia Pacific Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 165. Asia Pacific Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 166. China Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 167. China Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 168. China Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 169. China Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 170. Japan Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 171. Japan Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 172. Japan Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 173. Japan Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 174. India Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 175. India Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 176. India Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 177. India Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 178. South Korea Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 179. South Korea Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 180. South Korea Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 181. South Korea Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 182. Taiwan Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 183. Taiwan Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 184. Taiwan Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 185. Taiwan Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 186. Australia Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 187. Australia Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 188. Australia Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 189. Australia Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 190. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 191. Rest of Asia-Pacific Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 192. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 193. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 194. Europe Vaginal Candidiasis Sales, by Country K Units (2014-2019)
  • Table 195. Europe Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 196. Europe Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 197. Europe Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 198. Europe Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 199. Germany Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 200. Germany Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 201. Germany Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 202. Germany Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 203. France Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 204. France Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 205. France Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 206. France Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 207. Italy Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 208. Italy Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 209. Italy Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 210. Italy Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 211. United Kingdom Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 212. United Kingdom Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 213. United Kingdom Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 214. United Kingdom Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 215. Netherlands Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 216. Netherlands Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 217. Netherlands Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 218. Netherlands Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 219. Rest of Europe Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 220. Rest of Europe Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 221. Rest of Europe Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 222. Rest of Europe Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 223. MEA Vaginal Candidiasis Sales, by Country K Units (2014-2019)
  • Table 224. MEA Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 225. MEA Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 226. MEA Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 227. MEA Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 228. Middle East Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 229. Middle East Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 230. Middle East Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 231. Middle East Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 232. Africa Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 233. Africa Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 234. Africa Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 235. Africa Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 236. North America Vaginal Candidiasis Sales, by Country K Units (2014-2019)
  • Table 237. North America Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 238. North America Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 239. North America Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 240. North America Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 241. United States Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 242. United States Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 243. United States Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 244. United States Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 245. Canada Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 246. Canada Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 247. Canada Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 248. Canada Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 249. Mexico Vaginal Candidiasis Sales, by Treatment K Units (2014-2019)
  • Table 250. Mexico Vaginal Candidiasis Sales, by End-users K Units (2014-2019)
  • Table 251. Mexico Vaginal Candidiasis Sales, by Distribution Channel K Units (2014-2019)
  • Table 252. Mexico Vaginal Candidiasis Sales, by Symptoms K Units (2014-2019)
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Vaginal Candidiasis: by Treatment(USD Million)
  • Table 264. Vaginal Candidiasis Oral antifungal , by Region USD Million (2020-2025)
  • Table 265. Vaginal Candidiasis Topical imidazole , by Region USD Million (2020-2025)
  • Table 266. Vaginal Candidiasis: by End-users(USD Million)
  • Table 267. Vaginal Candidiasis Hospitals , by Region USD Million (2020-2025)
  • Table 268. Vaginal Candidiasis Clinics , by Region USD Million (2020-2025)
  • Table 269. Vaginal Candidiasis Others , by Region USD Million (2020-2025)
  • Table 270. Vaginal Candidiasis: by Distribution Channel(USD Million)
  • Table 271. Vaginal Candidiasis Hospital Pharmacies , by Region USD Million (2020-2025)
  • Table 272. Vaginal Candidiasis Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 273. Vaginal Candidiasis Online , by Region USD Million (2020-2025)
  • Table 274. Vaginal Candidiasis Others , by Region USD Million (2020-2025)
  • Table 275. Vaginal Candidiasis: by Symptoms(USD Million)
  • Table 276. Vaginal Candidiasis Vaginal itching or soreness , by Region USD Million (2020-2025)
  • Table 277. Vaginal Candidiasis Pain during sexual intercourse , by Region USD Million (2020-2025)
  • Table 278. Vaginal Candidiasis Pain or discomfort when urinating , by Region USD Million (2020-2025)
  • Table 279. Vaginal Candidiasis Abnormal vaginal discharge , by Region USD Million (2020-2025)
  • Table 280. South America Vaginal Candidiasis, by Country USD Million (2020-2025)
  • Table 281. South America Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 282. South America Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 283. South America Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 284. South America Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 285. Brazil Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 286. Brazil Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 287. Brazil Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 288. Brazil Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 289. Argentina Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 290. Argentina Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 291. Argentina Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 292. Argentina Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 293. Rest of South America Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 294. Rest of South America Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 295. Rest of South America Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 296. Rest of South America Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 297. Asia Pacific Vaginal Candidiasis, by Country USD Million (2020-2025)
  • Table 298. Asia Pacific Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 299. Asia Pacific Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 300. Asia Pacific Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 301. Asia Pacific Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 302. China Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 303. China Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 304. China Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 305. China Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 306. Japan Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 307. Japan Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 308. Japan Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 309. Japan Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 310. India Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 311. India Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 312. India Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 313. India Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 314. South Korea Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 315. South Korea Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 316. South Korea Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 317. South Korea Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 318. Taiwan Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 319. Taiwan Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 320. Taiwan Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 321. Taiwan Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 322. Australia Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 323. Australia Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 324. Australia Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 325. Australia Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 326. Rest of Asia-Pacific Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 327. Rest of Asia-Pacific Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 328. Rest of Asia-Pacific Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 329. Rest of Asia-Pacific Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 330. Europe Vaginal Candidiasis, by Country USD Million (2020-2025)
  • Table 331. Europe Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 332. Europe Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 333. Europe Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 334. Europe Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 335. Germany Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 336. Germany Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 337. Germany Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 338. Germany Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 339. France Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 340. France Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 341. France Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 342. France Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 343. Italy Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 344. Italy Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 345. Italy Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 346. Italy Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 347. United Kingdom Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 348. United Kingdom Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 349. United Kingdom Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 350. United Kingdom Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 351. Netherlands Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 352. Netherlands Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 353. Netherlands Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 354. Netherlands Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 355. Rest of Europe Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 356. Rest of Europe Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 357. Rest of Europe Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 358. Rest of Europe Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 359. MEA Vaginal Candidiasis, by Country USD Million (2020-2025)
  • Table 360. MEA Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 361. MEA Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 362. MEA Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 363. MEA Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 364. Middle East Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 365. Middle East Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 366. Middle East Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 367. Middle East Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 368. Africa Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 369. Africa Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 370. Africa Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 371. Africa Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 372. North America Vaginal Candidiasis, by Country USD Million (2020-2025)
  • Table 373. North America Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 374. North America Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 375. North America Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 376. North America Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 377. United States Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 378. United States Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 379. United States Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 380. United States Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 381. Canada Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 382. Canada Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 383. Canada Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 384. Canada Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 385. Mexico Vaginal Candidiasis, by Treatment USD Million (2020-2025)
  • Table 386. Mexico Vaginal Candidiasis, by End-users USD Million (2020-2025)
  • Table 387. Mexico Vaginal Candidiasis, by Distribution Channel USD Million (2020-2025)
  • Table 388. Mexico Vaginal Candidiasis, by Symptoms USD Million (2020-2025)
  • Table 389. Vaginal Candidiasis Sales: by Treatment(K Units)
  • Table 390. Vaginal Candidiasis Sales Oral antifungal , by Region K Units (2020-2025)
  • Table 391. Vaginal Candidiasis Sales Topical imidazole , by Region K Units (2020-2025)
  • Table 392. Vaginal Candidiasis Sales: by End-users(K Units)
  • Table 393. Vaginal Candidiasis Sales Hospitals , by Region K Units (2020-2025)
  • Table 394. Vaginal Candidiasis Sales Clinics , by Region K Units (2020-2025)
  • Table 395. Vaginal Candidiasis Sales Others , by Region K Units (2020-2025)
  • Table 396. Vaginal Candidiasis Sales: by Distribution Channel(K Units)
  • Table 397. Vaginal Candidiasis Sales Hospital Pharmacies , by Region K Units (2020-2025)
  • Table 398. Vaginal Candidiasis Sales Retail Pharmacies , by Region K Units (2020-2025)
  • Table 399. Vaginal Candidiasis Sales Online , by Region K Units (2020-2025)
  • Table 400. Vaginal Candidiasis Sales Others , by Region K Units (2020-2025)
  • Table 401. Vaginal Candidiasis Sales: by Symptoms(K Units)
  • Table 402. Vaginal Candidiasis Sales Vaginal itching or soreness , by Region K Units (2020-2025)
  • Table 403. Vaginal Candidiasis Sales Pain during sexual intercourse , by Region K Units (2020-2025)
  • Table 404. Vaginal Candidiasis Sales Pain or discomfort when urinating , by Region K Units (2020-2025)
  • Table 405. Vaginal Candidiasis Sales Abnormal vaginal discharge , by Region K Units (2020-2025)
  • Table 406. South America Vaginal Candidiasis Sales, by Country K Units (2020-2025)
  • Table 407. South America Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 408. South America Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 409. South America Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 410. South America Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 411. Brazil Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 412. Brazil Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 413. Brazil Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 414. Brazil Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 415. Argentina Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 416. Argentina Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 417. Argentina Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 418. Argentina Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 419. Rest of South America Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 420. Rest of South America Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 421. Rest of South America Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 422. Rest of South America Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 423. Asia Pacific Vaginal Candidiasis Sales, by Country K Units (2020-2025)
  • Table 424. Asia Pacific Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 425. Asia Pacific Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 426. Asia Pacific Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 427. Asia Pacific Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 428. China Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 429. China Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 430. China Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 431. China Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 432. Japan Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 433. Japan Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 434. Japan Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 435. Japan Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 436. India Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 437. India Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 438. India Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 439. India Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 440. South Korea Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 441. South Korea Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 442. South Korea Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 443. South Korea Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 444. Taiwan Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 445. Taiwan Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 446. Taiwan Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 447. Taiwan Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 448. Australia Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 449. Australia Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 450. Australia Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 451. Australia Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 452. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 453. Rest of Asia-Pacific Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 454. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 455. Rest of Asia-Pacific Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 456. Europe Vaginal Candidiasis Sales, by Country K Units (2020-2025)
  • Table 457. Europe Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 458. Europe Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 459. Europe Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 460. Europe Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 461. Germany Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 462. Germany Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 463. Germany Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 464. Germany Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 465. France Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 466. France Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 467. France Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 468. France Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 469. Italy Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 470. Italy Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 471. Italy Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 472. Italy Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 473. United Kingdom Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 474. United Kingdom Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 475. United Kingdom Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 476. United Kingdom Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 477. Netherlands Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 478. Netherlands Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 479. Netherlands Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 480. Netherlands Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 481. Rest of Europe Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 482. Rest of Europe Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 483. Rest of Europe Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 484. Rest of Europe Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 485. MEA Vaginal Candidiasis Sales, by Country K Units (2020-2025)
  • Table 486. MEA Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 487. MEA Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 488. MEA Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 489. MEA Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 490. Middle East Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 491. Middle East Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 492. Middle East Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 493. Middle East Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 494. Africa Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 495. Africa Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 496. Africa Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 497. Africa Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 498. North America Vaginal Candidiasis Sales, by Country K Units (2020-2025)
  • Table 499. North America Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 500. North America Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 501. North America Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 502. North America Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 503. United States Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 504. United States Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 505. United States Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 506. United States Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 507. Canada Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 508. Canada Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 509. Canada Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 510. Canada Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 511. Mexico Vaginal Candidiasis Sales, by Treatment K Units (2020-2025)
  • Table 512. Mexico Vaginal Candidiasis Sales, by End-users K Units (2020-2025)
  • Table 513. Mexico Vaginal Candidiasis Sales, by Distribution Channel K Units (2020-2025)
  • Table 514. Mexico Vaginal Candidiasis Sales, by Symptoms K Units (2020-2025)
  • Table 515. Research Programs/Design for This Report
  • Table 516. Key Data Information from Secondary Sources
  • Table 517. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Vaginal Candidiasis: by Treatment USD Million (2014-2019)
  • Figure 5. Global Vaginal Candidiasis: by End-users USD Million (2014-2019)
  • Figure 6. Global Vaginal Candidiasis: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Vaginal Candidiasis: by Symptoms USD Million (2014-2019)
  • Figure 8. South America Vaginal Candidiasis Share (%), by Country
  • Figure 9. Asia Pacific Vaginal Candidiasis Share (%), by Country
  • Figure 10. Europe Vaginal Candidiasis Share (%), by Country
  • Figure 11. MEA Vaginal Candidiasis Share (%), by Country
  • Figure 12. North America Vaginal Candidiasis Share (%), by Country
  • Figure 13. Global Vaginal Candidiasis: by Treatment K Units (2014-2019)
  • Figure 14. Global Vaginal Candidiasis: by End-users K Units (2014-2019)
  • Figure 15. Global Vaginal Candidiasis: by Distribution Channel K Units (2014-2019)
  • Figure 16. Global Vaginal Candidiasis: by Symptoms K Units (2014-2019)
  • Figure 17. South America Vaginal Candidiasis Share (%), by Country
  • Figure 18. Asia Pacific Vaginal Candidiasis Share (%), by Country
  • Figure 19. Europe Vaginal Candidiasis Share (%), by Country
  • Figure 20. MEA Vaginal Candidiasis Share (%), by Country
  • Figure 21. North America Vaginal Candidiasis Share (%), by Country
  • Figure 22. Global Vaginal Candidiasis share by Players 2019 (%)
  • Figure 23. Global Vaginal Candidiasis share by Players (Top 3) 2019(%)
  • Figure 24. Global Vaginal Candidiasis share by Players (Top 5) 2019(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Scynexis (United States) Revenue, Net Income and Gross profit
  • Figure 27. Scynexis (United States) Revenue: by Geography 2019
  • Figure 28. Synmedic Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 29. Synmedic Laboratories (India) Revenue: by Geography 2019
  • Figure 30. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck & Co., Inc. (United States) Revenue: by Geography 2019
  • Figure 32. Astellas (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Astellas (Japan) Revenue: by Geography 2019
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2019
  • Figure 36. Mentis Pharma Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 37. Mentis Pharma Ltd. (India) Revenue: by Geography 2019
  • Figure 38. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 39. Abbott (United States) Revenue: by Geography 2019
  • Figure 40. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 42. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 44. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 45. Sanofi (France) Revenue: by Geography 2019
  • Figure 46. Global Vaginal Candidiasis: by Treatment USD Million (2020-2025)
  • Figure 47. Global Vaginal Candidiasis: by End-users USD Million (2020-2025)
  • Figure 48. Global Vaginal Candidiasis: by Distribution Channel USD Million (2020-2025)
  • Figure 49. Global Vaginal Candidiasis: by Symptoms USD Million (2020-2025)
  • Figure 50. South America Vaginal Candidiasis Share (%), by Country
  • Figure 51. Asia Pacific Vaginal Candidiasis Share (%), by Country
  • Figure 52. Europe Vaginal Candidiasis Share (%), by Country
  • Figure 53. MEA Vaginal Candidiasis Share (%), by Country
  • Figure 54. North America Vaginal Candidiasis Share (%), by Country
  • Figure 55. Global Vaginal Candidiasis: by Treatment K Units (2020-2025)
  • Figure 56. Global Vaginal Candidiasis: by End-users K Units (2020-2025)
  • Figure 57. Global Vaginal Candidiasis: by Distribution Channel K Units (2020-2025)
  • Figure 58. Global Vaginal Candidiasis: by Symptoms K Units (2020-2025)
  • Figure 59. South America Vaginal Candidiasis Share (%), by Country
  • Figure 60. Asia Pacific Vaginal Candidiasis Share (%), by Country
  • Figure 61. Europe Vaginal Candidiasis Share (%), by Country
  • Figure 62. MEA Vaginal Candidiasis Share (%), by Country
  • Figure 63. North America Vaginal Candidiasis Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Scynexis (United States)
  • Synmedic Laboratories (India)
  • Merck & Co., Inc. (United States)
  • Astellas (Japan)
  • Bayer AG (Germany)
  • Mentis Pharma Ltd. (India)
  • Abbott (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
Additional players considered in the study are as follows:
ALLERGAN (Ireland) , AstraZeneca (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation